Search

• GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk

  Media

  GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.

  https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/

  First published: 06 February 2024

• New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease

  Media

  Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.

  https://www.gsk.com/en-gb/media/press-releases/new-data-for-arexvy-show-potential-to-help-protect-adults-aged-50-to-59/

  First published: 25 October 2023

• Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults

  Media

  Arexvy’s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time

  https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-gsk-s-arexvy/

  First published: 25 September 2023

• Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk

  Media

  Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.

  https://www.gsk.com/en-gb/media/press-releases/japan-accepts-arexvy-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59/

  First published: 12 December 2023

• Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine

  Media

  This confirmation follows the announcement on 31 July of advanced discussions between the companies and the EC.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/

  First published: 18 September 2020

• Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

  Media

  Over 400 participants being enrolled in Phase 1/2 study.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/

  First published: 03 September 2020

• Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

  Media

  New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-new-phase-2-study-of-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate/

  First published: 22 February 2021

• Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

  Media

  Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.

  https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/

  First published: 12 November 2020

• Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly

  Media

  Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/

  First published: 11 December 2020

• GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute

  Media

  Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines

  https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/

  First published: 06 August 2019